Hovione Appoints Terry Lambe to its Board of Directors

Hovione Appoints Terry Lambe to its Board of Directors

CORK, Ireland, September 10 /PRNewswire/ -- Hovione announced today that
Terry Lambe, Ph.D., has been elected to the Board of Directors of Hovione Ltd.
    Hovione acquired earlier this year an important API manufacturing site
located in Cork. This is a key element of the Hovione strategy to become a
leading manufacturer to the pharmaceutical industry.
    "We are delighted to welcome Terry Lambe to Hovione. We want to build our
Cork site into the ideal, preferred, launch facility for new product
introductions. In the context of the emerging business model based on
outsourcing, our Cork site provides innovator pharmaceutical companies with
all the benefits of a top manufacturing facility without the costs of
ownership. Terry has a good understanding of what Large Pharma requires and
brings to Hovione a wealth of international experience in manufacturing
activities. We also feel that to do this right it is important to have on the
board of our subsidiary company in Ireland someone familiar with the local
culture and with strong links into the Irish pharmachem industry," said Guy
Villax, Hovione's Chief Executive. In addition Terry also becomes a member of
the Hovione Manufacturing Committee that sets out the longer-term production
strategy for the group.
    "I am enthusiastic about joining a successful and dynamic company like
Hovione and I hope to be able to make a significant contribution to its
profitable growth," said Dr. Lambe.
    Dr. Terry Lambe joins Hovione following his retirement from Pfizer Inc.
in 2008. Dr. Lambe worked at Pfizer for 30 years, during this time he held
roles of increasing responsibility in manufacturing and was responsible for
the construction of several API facilities in Puerto Rico, in Groton,
Connecticut and later in Singapore. In 1999, Dr. Lambe assumed his role as
Vice President, Global Drug Substance. In 2000, he was appointed Team Leader
/ Vice President, Ireland / Singapore Manufacturing Area, a position he held
until 2008. In 2004, Dr. Lambe was awarded the Bio-Link USA - Ireland Life
Science Award for his contribution to the Pharmaceutical Industry. He holds a
B.S. and a Ph.D. in Chemistry from University College Cork and completed a
post-doctoral fellowship in Electro-Fluorination Chemistry at the University
of Manchester.
    About Hovione
    Hovione is an international company with 50 years' experience in active
pharmaceutical ingredient development and compliant manufacture. With four
FDA inspected sites in the US, China, Ireland and Portugal the company
focuses on the most demanding customers in the most highly regulated markets.
The company also offers integrated API, particle design and formulation
development and manufacturing. In the inhalation area Hovione is the only
independent company offering such a broad range of services.
    For more information about Hovione, please visit the Hovione site at
http://www.hovione.com or contact Corporate Communications, Isabel Pina,
+351-21-982-9362, e-mail: [email protected]
SOURCE  Hovion

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.